Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis

Introduction: Benralizumab, mepolizumab, and reslizumab are novel monoclonal antibodies approved for asthma, targeting eosinophilic inflammation. Benralizumab is directed against IL-5 receptor (IL-5R), while mepolizumab and reslizumab are directed against IL-5. The three drugs cause a reduction in e...

Description complète

Détails bibliographiques

Auteurs principaux:	Riccardo Giossi, Arianna Pani, Jan Schroeder, Francesco Scaglione
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2024-01-01
Collection:	Heliyon
Sujets:	Benralizumab Mepolizumab Reslizumab IL-5 Infection Meta-analysis
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2405844023109339
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!